Literature DB >> 1658990

Kala-azar in displaced people from southern Sudan: epidemiological, clinical and therapeutic findings.

E E Zijlstra1, M S Ali, A M el-Hassan, I A el-Toum, M Satti, H W Ghalib, E Sondorp, A Winkler.   

Abstract

Six hundred and ninety-three patients with kala-azar were seen in Khartoum, Sudan, from January 1989 to February 1990. They were almost exclusively from the Nuer tribe, originating from the western Upper Nile province in southern Sudan, an area not known previously to be endemic for kala-azar. Because of the civil war in southern Sudan no treatment was available locally and massive migration to northern Sudan occurred; many died on the way. All age groups were affected; there was a slight male preponderance (56%). In the clinical presentation, marked generalized lymphadenopathy was prominent (84%). Splenomegaly was absent in 4% of cases. Patients usually showed anaemia, leucopenia and/or thrombocytopenia. 623 patients were treated with sodium stibogluconate, 10 mg/kg for 30 d; relapse occurred in 4% and death in 12%. Latterly, 70 patients were treated with sodium stibogluconate at 2 x 10 mg/kg for 15 d, with relapse in 6% and death in 6%. The difference between the 2 regimens in the number of relapses and deaths was not significant. The outbreak may have been caused by a combination of factors: the introduction of the parasite from an endemic area to a non-immune population, the presence of malnutrition caused by loss of cattle and unavailability of other food sources, and possibly an ecological change in favour of the sandfly vector.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1658990     DOI: 10.1016/0035-9203(91)90293-8

Source DB:  PubMed          Journal:  Trans R Soc Trop Med Hyg        ISSN: 0035-9203            Impact factor:   2.184


  12 in total

Review 1.  Prevalence, severity, and pathogeneses of anemia in visceral leishmaniasis.

Authors:  Yasuyuki Goto; Jingjie Cheng; Satoko Omachi; Ayako Morimoto
Journal:  Parasitol Res       Date:  2016-11-07       Impact factor: 2.289

2.  The significance of blood levels of IgM, IgA, IgG and IgG subclasses in Sudanese visceral leishmaniasis patients.

Authors:  A M Elassad; S A Younis; M Siddig; J Grayson; E Petersen; H W Ghalib
Journal:  Clin Exp Immunol       Date:  1994-02       Impact factor: 4.330

3.  Leishmania resistant to sodium stibogluconate: drug-associated macrophage-dependent killing.

Authors:  M E Ibrahim; M Hag-Ali; A M el-Hassan; T G Theander; A Kharazmi
Journal:  Parasitol Res       Date:  1994       Impact factor: 2.289

4.  Liver morphology and function in visceral leishmaniasis (Kala-azar).

Authors:  I A el Hag; F A Hashim; I A el Toum; M Homeida; M el Kalifa; A M el Hassan
Journal:  J Clin Pathol       Date:  1994-06       Impact factor: 3.411

5.  Epistaxis in visceral leishmaniasis with hematological correlation.

Authors:  B Sigdel; S Bhandary; S Rijal
Journal:  Int J Otolaryngol       Date:  2012-01-04

6.  Visceral leishmaniasis outbreak in South Sudan 2009-2012: epidemiological assessment and impact of a multisectoral response.

Authors:  Abdinasir Abubakar; José Antonio Ruiz-Postigo; Jane Pita; Mounir Lado; Riadh Ben-Ismail; Daniel Argaw; Jorge Alvar
Journal:  PLoS Negl Trop Dis       Date:  2014-03-27

7.  The Schistosoma mansoni hepatic egg granuloma provides a favorable microenvironment for sustained growth of Leishmania donovani.

Authors:  Mohammed F Hassan; Yaobi Zhang; Christian R Engwerda; Paul M Kaye; Hannah Sharp; Quentin D Bickle
Journal:  Am J Pathol       Date:  2006-09       Impact factor: 4.307

Review 8.  Identifying the research gap of zoonotic disease in displacement: a systematic review.

Authors:  Dorien Hanneke Braam; Freya Louise Jephcott; James Lionel Norman Wood
Journal:  Glob Health Res Policy       Date:  2021-07-16

Review 9.  Complexities of assessing the disease burden attributable to leishmaniasis.

Authors:  Caryn Bern; James H Maguire; Jorge Alvar
Journal:  PLoS Negl Trop Dis       Date:  2008-10-29

10.  Combination therapy using Pentostam and Praziquantel improves lesion healing and parasite resolution in BALB/c mice co-infected with Leishmania major and Schistosoma mansoni.

Authors:  Christopher Khayeka-Wandabwa; Helen Kutima; Venny C S Nyambati; Johnstone Ingonga; Elijah Oyoo-Okoth; Lucy Karani; Bernard Jumba; Kiige Githuku; Christopher O Anjili
Journal:  Parasit Vectors       Date:  2013-08-22       Impact factor: 3.876

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.